JP2013503174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503174A5 JP2013503174A5 JP2012526948A JP2012526948A JP2013503174A5 JP 2013503174 A5 JP2013503174 A5 JP 2013503174A5 JP 2012526948 A JP2012526948 A JP 2012526948A JP 2012526948 A JP2012526948 A JP 2012526948A JP 2013503174 A5 JP2013503174 A5 JP 2013503174A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- medicament according
- medicament
- albumin
- hedgehog inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000289669 Erinaceus europaeus Species 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 20
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 229940123237 Taxane Drugs 0.000 claims description 17
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 17
- 102000009027 Albumins Human genes 0.000 claims description 14
- 108010088751 Albumins Proteins 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
- 229960005277 gemcitabine Drugs 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- KLRRGBHZCJLIEL-UHFFFAOYSA-N n-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide Chemical compound CNCC1=CC=C(C)C(NC(=O)C=2C=CC(NC=3N=C4C=CC=CC4=C(C=4C=CC=CC=4)N=3)=CC=2)=C1 KLRRGBHZCJLIEL-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
- 229960005569 saridegib Drugs 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 229960005325 sonidegib Drugs 0.000 claims description 2
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960004449 vismodegib Drugs 0.000 claims description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical group ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 30
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000011146 sterile filtration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23681309P | 2009-08-25 | 2009-08-25 | |
| US61/236,813 | 2009-08-25 | ||
| PCT/US2010/046684 WO2011025838A1 (en) | 2009-08-25 | 2010-08-25 | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013503174A JP2013503174A (ja) | 2013-01-31 |
| JP2013503174A5 true JP2013503174A5 (enExample) | 2013-10-10 |
Family
ID=43628371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012526948A Pending JP2013503174A (ja) | 2009-08-25 | 2010-08-25 | タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20130045240A1 (enExample) |
| EP (2) | EP2470173B1 (enExample) |
| JP (1) | JP2013503174A (enExample) |
| KR (1) | KR20120053052A (enExample) |
| CN (1) | CN102573832B (enExample) |
| AU (1) | AU2010286670B2 (enExample) |
| BR (1) | BR112012004149A2 (enExample) |
| CA (1) | CA2772301A1 (enExample) |
| CR (1) | CR20120115A (enExample) |
| DK (1) | DK2470173T3 (enExample) |
| ES (1) | ES2577024T3 (enExample) |
| HR (1) | HRP20160551T8 (enExample) |
| HU (1) | HUE029094T2 (enExample) |
| IL (1) | IL218316A (enExample) |
| IN (1) | IN2012DN02018A (enExample) |
| MX (1) | MX340670B (enExample) |
| MY (1) | MY162514A (enExample) |
| NI (1) | NI201200030A (enExample) |
| NZ (1) | NZ598588A (enExample) |
| PL (1) | PL2470173T3 (enExample) |
| PT (1) | PT2470173E (enExample) |
| RU (1) | RU2561055C2 (enExample) |
| SG (2) | SG10201609290PA (enExample) |
| UA (1) | UA110196C2 (enExample) |
| WO (1) | WO2011025838A1 (enExample) |
| ZA (1) | ZA201201531B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| NZ595313A (en) | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| CA2880727C (en) * | 2005-08-31 | 2019-05-07 | Neil P. Desai | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20150002886A (ko) * | 2007-03-07 | 2015-01-07 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| PL2552438T3 (pl) | 2010-03-26 | 2016-12-30 | Sposoby leczenia raka wątrobowokomórkowego | |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| CA2797694A1 (en) | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Activators of human pyruvate kinase |
| SG186109A1 (en) * | 2010-06-02 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| JP6257324B2 (ja) * | 2010-06-04 | 2018-01-10 | アブラクシス バイオサイエンス， エルエルシー | 膵臓がんの処置方法 |
| EP3056201A1 (en) * | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| US8779149B2 (en) * | 2010-08-23 | 2014-07-15 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| US8945627B2 (en) | 2011-05-05 | 2015-02-03 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
| SMT201900502T1 (it) | 2011-12-14 | 2019-11-13 | Abraxis Bioscience Llc | Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle |
| US9248128B2 (en) | 2012-01-27 | 2016-02-02 | New York University | Method for enhancing remyelination using GLI1 inhibitors |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| WO2014062511A1 (en) * | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014087413A1 (en) * | 2012-12-03 | 2014-06-12 | Vishwa Vidya Peetham University Amrita | Nanoparticles comprising sorafenib |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) * | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| WO2014144747A1 (en) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2014179678A1 (en) * | 2013-05-03 | 2014-11-06 | Angiostrass Llc | Methods of treating cancer and angioproliferative disorders |
| RU2681849C2 (ru) * | 2013-06-05 | 2019-03-13 | Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ | Гетероциклические производные и их применение |
| TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物 |
| JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| AR097685A1 (es) * | 2013-09-17 | 2016-04-06 | Genentech Inc | Métodos de uso de anticuerpos anti-lgr5 |
| GB201416513D0 (en) | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| WO2016138479A1 (en) | 2015-02-27 | 2016-09-01 | Curtana Pharmaceuticals, Inc. | Inhibition of olig2 activity |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| CA2986083A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
| JP6987644B2 (ja) | 2015-06-29 | 2022-01-05 | アブラクシス バイオサイエンス， エルエルシー | 類上皮細胞腫瘍を処置する方法 |
| CN106421786A (zh) * | 2015-08-06 | 2017-02-22 | 复旦大学 | Hedgehog通路抑制剂和纳米药物递送系统的药物组合物及其用途 |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| JP2022543021A (ja) * | 2019-05-29 | 2022-10-07 | ネルム コーポレーション | がんを処置する方法及び使用 |
| WO2021086946A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CN112755042A (zh) * | 2019-11-06 | 2021-05-07 | 绍兴维帆生物技术有限公司 | 一种抗肿瘤药物的联合使用治疗白血病的方法 |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| WO2025120550A1 (ko) * | 2023-12-08 | 2025-06-12 | 제이더블유중외제약 주식회사 | 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법 |
| WO2025120551A1 (ko) * | 2023-12-08 | 2025-06-12 | 제이더블유중외제약 주식회사 | 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법 |
| CN120177781B (zh) * | 2025-05-22 | 2025-08-12 | 南京师范大学 | 生物传感器及其应用和高通量筛选花姜酮生产菌的方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| KR100904931B1 (ko) * | 1997-06-27 | 2009-06-29 | 아브락시스 바이오사이언스, 엘엘씨 | 나노 입자 및 그의 제조 방법 |
| EP1133519B1 (en) | 1998-11-02 | 2008-08-13 | Curis, Inc. | Functional antagonists of hedgehog activity |
| US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| AU767066B2 (en) | 1999-03-03 | 2003-10-30 | Curis, Inc. | Methods of modulating lipid metabolism and storage |
| AU782493B2 (en) | 1999-06-01 | 2005-08-04 | Curis, Inc. | Polymer conjugates of hedgehog proteins and uses |
| US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| US20050192262A1 (en) * | 2001-03-13 | 2005-09-01 | Tomas Hagstrom | Treatment of tumours |
| WO2003011219A2 (en) | 2001-07-27 | 2003-02-13 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ATE404200T1 (de) | 2002-04-22 | 2008-08-15 | Univ Johns Hopkins Med | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| FR2850022B1 (fr) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| US20070281040A1 (en) * | 2004-09-30 | 2007-12-06 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
| CA2587489C (en) * | 2004-11-03 | 2013-12-31 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| NZ595313A (en) * | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| KR101643416B1 (ko) | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
| JP2009514889A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法 |
| AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| WO2008121102A2 (en) | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
| DE102006038747A1 (de) | 2006-08-17 | 2008-03-20 | Khs Ag | Dichtanordnung für eine Drehlagervorrichtung |
| JP4897518B2 (ja) | 2007-03-02 | 2012-03-14 | 株式会社ニチベイ | ブラインドの操作装置 |
| JP5577104B2 (ja) * | 2007-03-14 | 2014-08-20 | エクセリクシス パテント カンパニー エルエルシー | ヘッジホッグ経路の阻害剤 |
| JP5550352B2 (ja) * | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| JP5373777B2 (ja) * | 2007-06-07 | 2013-12-18 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ヘッジホッグ経路モジュレーターとしてのビフェニルカルボキサミド誘導体 |
| US20090123932A1 (en) * | 2007-11-09 | 2009-05-14 | Anne-Marie Mes-Masson | Quantitative test to detect disease progression markers of epithelial ovarian cancer patients |
| CN101918420A (zh) * | 2007-12-27 | 2010-12-15 | 无限药品股份有限公司 | 癌症治疗方法 |
| EP2235063B1 (en) * | 2007-12-28 | 2015-09-02 | Genentech, Inc. | Anti-hedgehog antibodies |
-
2010
- 2010-08-25 CN CN201080045983.0A patent/CN102573832B/zh active Active
- 2010-08-25 JP JP2012526948A patent/JP2013503174A/ja active Pending
- 2010-08-25 BR BR112012004149A patent/BR112012004149A2/pt not_active Application Discontinuation
- 2010-08-25 NZ NZ598588A patent/NZ598588A/en not_active IP Right Cessation
- 2010-08-25 WO PCT/US2010/046684 patent/WO2011025838A1/en not_active Ceased
- 2010-08-25 HR HRP20160551TT patent/HRP20160551T8/hr unknown
- 2010-08-25 PL PL10812593.1T patent/PL2470173T3/pl unknown
- 2010-08-25 EP EP10812593.1A patent/EP2470173B1/en active Active
- 2010-08-25 ES ES10812593.1T patent/ES2577024T3/es active Active
- 2010-08-25 CA CA2772301A patent/CA2772301A1/en not_active Abandoned
- 2010-08-25 DK DK10812593.1T patent/DK2470173T3/en active
- 2010-08-25 RU RU2012111235/15A patent/RU2561055C2/ru active
- 2010-08-25 SG SG10201609290PA patent/SG10201609290PA/en unknown
- 2010-08-25 AU AU2010286670A patent/AU2010286670B2/en active Active
- 2010-08-25 MY MYPI2012000838A patent/MY162514A/en unknown
- 2010-08-25 UA UAA201203446A patent/UA110196C2/uk unknown
- 2010-08-25 KR KR1020127007526A patent/KR20120053052A/ko not_active Ceased
- 2010-08-25 SG SG2012013157A patent/SG178873A1/en unknown
- 2010-08-25 EP EP16167017.9A patent/EP3103452A1/en not_active Withdrawn
- 2010-08-25 HU HUE10812593A patent/HUE029094T2/hu unknown
- 2010-08-25 US US13/392,501 patent/US20130045240A1/en not_active Abandoned
- 2010-08-25 IN IN2018DEN2012 patent/IN2012DN02018A/en unknown
- 2010-08-25 MX MX2012002460A patent/MX340670B/es active IP Right Grant
- 2010-08-25 PT PT108125931T patent/PT2470173E/pt unknown
-
2012
- 2012-02-24 NI NI201200030A patent/NI201200030A/es unknown
- 2012-02-26 IL IL218316A patent/IL218316A/en active IP Right Grant
- 2012-02-29 ZA ZA2012/01531A patent/ZA201201531B/en unknown
- 2012-03-12 CR CR20120115A patent/CR20120115A/es unknown
-
2013
- 2013-02-28 US US13/781,487 patent/US20140072630A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503174A5 (enExample) | ||
| RU2012111235A (ru) | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог | |
| Liu et al. | The antitumor effect of novel docetaxel-loaded thermosensitive micelles | |
| JP2012506448A5 (enExample) | ||
| Abouzeid et al. | Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer | |
| JP5805071B2 (ja) | Ｄｎａ損傷因子増強のためのチェックポイントキナーゼ１阻害剤 | |
| JP2013527232A5 (enExample) | ||
| JP2013523656A5 (enExample) | ||
| JP2010523696A5 (enExample) | ||
| JP2016513657A5 (enExample) | ||
| JP2010180210A5 (enExample) | ||
| JP2016513097A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| Samadi et al. | Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells | |
| JP2017226708A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| JP2016512513A5 (enExample) | ||
| JP2019521180A5 (enExample) | ||
| JP2007509978A5 (enExample) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| JP2015515475A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2011507838A5 (enExample) | ||
| JP2016515586A5 (enExample) | ||
| D’Addio et al. | Antitubercular nanocarrier combination therapy: Formulation strategies and in vitro efficacy for rifampicin and SQ641 |